147
147
Oct 16, 2012
10/12
by
WBAL
tv
eye 147
favorite 0
quote 0
but under the surface, intercept and kythera have a lot in common where it counts.intercept also has funding. they weren't going public because they needed cash. that's been a pitfall for other biotech ipos. intercept has a quality management team. has been there for a decade. chief medical officer used to have the same position before it was sold to pfizer in 2005 and spent time as a consultant. again, this ipo had all the right ingredients, and therefore it spiked more than 29% on the first day. shutter stock, fast-growing supplier of pro shot digital imagery. 27.4% on day one. fleetmatics managed to buck the trend. how? what was the synergy? what characteristics did that share? well, the company is a software as a service unit, just like workday, just like salesforce. with software for companies with commercial vehicle fleets. and last year grew at a 43% clip. there was nothing inherently bad about the week before last. it's just of the last six ipos priced that week, most were not like fleetmatics. what was wrong with them? let's go for some commonalities there
but under the surface, intercept and kythera have a lot in common where it counts.intercept also has funding. they weren't going public because they needed cash. that's been a pitfall for other biotech ipos. intercept has a quality management team. has been there for a decade. chief medical officer used to have the same position before it was sold to pfizer in 2005 and spent time as a consultant. again, this ipo had all the right ingredients, and therefore it spiked more than 29% on the first...
134
134
Oct 12, 2012
10/12
by
KQEH
tv
eye 134
favorite 0
quote 0
a quartet of companies made their trading debut-- realogy, shutterstock, kythera pharmaceuticals, and intercept pharmaceuticals posting decent gains of 20% or better. oil trimmed some of its gains in the session after a government report showed a slightly higher than expected increase in u.s. supplies last week. it ended back above $92 a barrel. heating oil and natural gas futures rallied. the same government report also forecast a rise in spending for winter heating fuels. heating oil is at a six-month high, and natural gas prices are at new highs for the year. those rising prices are making coal look more attractive. peabody and consol energy rose at least 8%. alpha natural and arch coal were up even stronger. looking ahead to tomorrow, j.p. morgan and wells fargo will report third quarter results before the opening bell. shares of j.p. morgan moved slightly higher on word that the bank's c.f.o. will step down and move into a different position. j.p. morgan is expected to post profits of $1.21 a share; that's 19 cents above last year's numbers. wells fargo is expected to earn 87 cen
a quartet of companies made their trading debut-- realogy, shutterstock, kythera pharmaceuticals, and intercept pharmaceuticals posting decent gains of 20% or better. oil trimmed some of its gains in the session after a government report showed a slightly higher than expected increase in u.s. supplies last week. it ended back above $92 a barrel. heating oil and natural gas futures rallied. the same government report also forecast a rise in spending for winter heating fuels. heating oil is at a...
171
171
Oct 11, 2012
10/12
by
FBC
tv
eye 171
favorite 0
quote 0
we have intercept pharmaceuticals, realogy, kythera and then shuttershock. all up. then we get to home depot, is the performance too good to be true? yesterday analysts said this company has done so well, it is bound to trip up. will it? coming up this hour, we're speaking exclusively to the chairman, president and ceo of home depot, frank blake. this is a rare interview. he rarely speaks to the media, but you know what? he is speaking to fox business to tell the home depot story. the analyst who downgraded him yesterday, you don't see that very often, downgrading home depot, it is up about 78% year over year. we're going to talk to frank about how he plans to prove them wrong, how he plans to keep building up the business. trust us, you cannot afford to miss this interview with frank blake, the chairman and ceo of home depot. in the meantime, we can never miss our floor show. traders at the new york stock exchange, cme group and the nymex. i want you to join in on this conversation. we can start at least with john. you tell me, john, to lose an 80 point lead is pre
we have intercept pharmaceuticals, realogy, kythera and then shuttershock. all up. then we get to home depot, is the performance too good to be true? yesterday analysts said this company has done so well, it is bound to trip up. will it? coming up this hour, we're speaking exclusively to the chairman, president and ceo of home depot, frank blake. this is a rare interview. he rarely speaks to the media, but you know what? he is speaking to fox business to tell the home depot story. the analyst...
298
298
Oct 11, 2012
10/12
by
CNBC
tv
eye 298
favorite 0
quote 0
one has been postponed but you got realogy holdings, intercept and kythera and shutterstock and garrisonng in, expected to go public but it postponed its ipo due to market conditions or maybe what the pricing wound up on that one. when we come back, we have breaking economic numbers and international trade data for august and import/export prices for september, the jobs number will be the one people are watching. as we head to a break look at the u.s. equity futures ahead of the numbers, positive territory for all three of those indices, dow futures up by 42, and this comes after three down days for the dow, another triple-digit loss yesterday. tdd#: 1-800-345-2550 let's talk about low-cost investing. tdd#: 1-800-345-2550 at schwab, we're committed to offering you tdd#: 1-800-345-2550 low-cost investment options-- tdd#: 1-800-345-2550 like our exchange traded funds, or etfs tdd#: 1-800-345-2550 which now have the lowest tdd#: 1-800-345-2550 operating expenses tdd#: 1-800-345-2550 in their respective tdd#: 1-800-345-2550 lipper categories. tdd#: 1-800-345-2550 lower than spdr tdd#: 1-800-
one has been postponed but you got realogy holdings, intercept and kythera and shutterstock and garrisonng in, expected to go public but it postponed its ipo due to market conditions or maybe what the pricing wound up on that one. when we come back, we have breaking economic numbers and international trade data for august and import/export prices for september, the jobs number will be the one people are watching. as we head to a break look at the u.s. equity futures ahead of the numbers,...
100
100
Oct 11, 2012
10/12
by
CNBC
tv
eye 100
favorite 0
quote 0
kythera. they make injections that go under your chin to get rid of the fat. >> two for one, bob.ould i definitely do with that. >> talking about the next one, another biotech firm. these firms don't open up big like this. intercept. they deal with problems with the liver. liver disease. very important, big growth area, priced at $15. opened at $19.40. still holding up here. finally, here's one i bet you are wondering why is it doing so well. a commercial stock -- shutterstock. why are they doing so well? you're a company. you want a brochure. you don't want to spend a fortune for photography. you want to go online, buy some noise photographs for a few dollars, drop them into your brochure, boom, you own it forever. that's the idea behind it. mandy, 60% margins. >> 60%! bob, stick around. stick around. want to bring herb into the conversation. herb has been a pretty lousy year for ipos. what do you make of this? >> kind of interesting, makes me wonder what happened to that recent string of ipos where people said there were canceling for market conditions. we were talking about tha
kythera. they make injections that go under your chin to get rid of the fat. >> two for one, bob.ould i definitely do with that. >> talking about the next one, another biotech firm. these firms don't open up big like this. intercept. they deal with problems with the liver. liver disease. very important, big growth area, priced at $15. opened at $19.40. still holding up here. finally, here's one i bet you are wondering why is it doing so well. a commercial stock -- shutterstock. why...
293
293
Oct 11, 2012
10/12
by
CNBC
tv
eye 293
favorite 0
quote 0
kythera biopharma. priced at 16. opened at $18.49. trading up as well.a real big day for ipos. success across the board. let me move on. we're up today. a good portion of the reason we're up, energy stocks were really hot. a big call out of the morgan stanley this morning on natural gas. the analyst there bullish on nat gas. demand is elevated. inventory is moving from supply to a deficit. that's been going on for a while here at the surplus. and what about that switching from coal to natural gas that everybody talks about? the prices have got to rally even more for that process to sort of switch off here. really bullish overall. take a look at nat gas. important thing here, of course, been depressed for ages. finally coming well off lows. look at this. sitting right here. highs for the year on nat gas. big names are all up. southwest, chesapeake, cabot, devon. coal stocks up as well. wait a minute. coal or nat gas, usually in opposition to each other. why are coal stocks doing so well? they've been beaten up badly. also if the prices of nat gas keep ral
kythera biopharma. priced at 16. opened at $18.49. trading up as well.a real big day for ipos. success across the board. let me move on. we're up today. a good portion of the reason we're up, energy stocks were really hot. a big call out of the morgan stanley this morning on natural gas. the analyst there bullish on nat gas. demand is elevated. inventory is moving from supply to a deficit. that's been going on for a while here at the surplus. and what about that switching from coal to natural...
332
332
Oct 11, 2012
10/12
by
FBC
tv
eye 332
favorite 0
quote 0
and kythera bio pharma is up 20%. back to you. tracy: see you soon, nicole.president joe biden and representative paul ryan will take center stage tonight at the only vice presidential debate of the campaign season. the latest fox news poll showing 46% of americans have a favorable opinion of paul ryan compared to 44% for the vice president. fox news senior vice president, managing editor neil cavuto in danville kentucky with a preview of the debate tonight. it feels as if this debate takes on perhaps more importance in the normal vp debate would in the wake of the president's debate, what do you think? >> i think you are right, ashley. that debate really got concerns growing among the entire white house staff and those outside saying, you know, we have got to get this thing back on track, and so they are looking to joe biden to do it. and a lot of republicans dismiss joe biden. they say, you know, he says a lot of crazy stuff and all that, but keep in mind, talk about your -- he was elected to senate when paul ryan was only 3 years old. having said that, bef
and kythera bio pharma is up 20%. back to you. tracy: see you soon, nicole.president joe biden and representative paul ryan will take center stage tonight at the only vice presidential debate of the campaign season. the latest fox news poll showing 46% of americans have a favorable opinion of paul ryan compared to 44% for the vice president. fox news senior vice president, managing editor neil cavuto in danville kentucky with a preview of the debate tonight. it feels as if this debate takes on...